Relator Alleged Defendants Used Misleading Information to Obtain Grants. Why Did the Third Circuit Affirm Dismissal of the Suit?
Relator brought a qui tam action under the FCA, alleging several pharmaceutical companies fraudulently induced FDA grants by providing misleading information about the serious side effects of antibiotics.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.